Document is current
Any future updates will be listed below
-
Authors
Marderstein, Andrew R. https://orcid.org/0000-0003-0859-4969
Kundu, Soumya https://orcid.org/0000-0001-5182-5326
Padhi, Evin M.
Deshpande, Salil
Wang, Austin
Robb, Esther
Sun, Ying https://orcid.org/0009-0006-4839-299X
Yun, Chang M. https://orcid.org/0000-0003-3793-8265
Pomales-Matos, Diego
Xie, Yilin
Chang, Serena H. https://orcid.org/0009-0007-2908-9546
Chin, Iris M.
Shah, Aayushi J. https://orcid.org/0009-0007-2070-5517
Gardell, Zachary A.
Corces, M. Ryan https://orcid.org/0000-0001-7465-7652
Nachun, Daniel
Jessa, Selin https://orcid.org/0000-0003-4192-6523
Kundaje, Anshul https://orcid.org/0000-0003-3084-2287
Montgomery, Stephen B. https://orcid.org/0000-0002-5200-3903
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5U01HG012069-03)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5U01HG012069-03)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5U01HG012069-03)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5U01HG012069-03)
- License Information
-
More Information
Article History
Received: 18 February 2025
Accepted: 28 April 2026
First Online: 15 June 2026
Competing interests
: S.B.M. is an advisor to BridgeBio, MyOme and PhiTech. During the time of this project but unrelated to this work, A.R.M. consulted for Pfizer Inc. and Third Rock Ventures (Marea Therapeutics). A.K. is on the scientific advisory boards of SerImmune, TensorBio and AINovo; is a consultant with Arcardia Science, Inari, Precede Biosciences and Bristol Myers Squibb; was a consultant with Illumina and PatchBio; and has a financial stake in DeepGenomics, SerImmune, Immunai and Freenome. The other authors declare no competing interests.
